Oral bowel cleansers and ischemic colitis risk: A real-world disproportionality analysis
Fig 5
Distribution of adverse event outcomes.
(a) Outcomes of cases using bisacodyl. (b) Outcomes of cases using PEG. (c) Outcomes of cases using OSS. (d) Outcomes among female patients. (e) Outcomes among male patients.